Trial Profile

A multicenter, phase 1/2, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OSE 2101 (Primary) ; OSE-279 (Primary)
Indications Alveolar soft part sarcoma; Anal cancer; Liver cancer; Lymphoma; Malignant fibrous histiocytoma; Sarcoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Tumour lysis syndrome
Focus Adverse reactions; First in man
Sponsors OSE Immunotherapeutics

Most Recent Events

09 Sep 2025 Planned number of patients changed from 55 to 41.
04 Jul 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2029.
04 Jul 2025 Planned primary completion date changed from 1 Oct 2024 to 1 Dec 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com